S'abonner

SECONDARY PULMONARY MALIGNANCY - 06/09/11

Doi : 10.1016/S0039-6109(05)70204-8 
James P. Greelish, MD *, Joseph S. Friedberg, MD *

Résumé

After the liver, the lung is the second most common site for metastatic involvement in neoplastic disease when all histologies are considered. Consequently, 20% to 54% of patients with cancer have pulmonary metastases at some point in the natural history of their disease. In the absence of extrathoracic metastases (25% of patients with disseminated disease), complete resection is associated with increased survival, regardless of histology. With appropriate patient selection, life expectancy is often improved, and in some cases, cures are reported with resection alone or in combination with chemotherapy.15, 143 Even in the context of unresectability, surgical forms of palliation often improve quality of life. For other patients (e.g., those with nonseminomatous germ-cell tumors), surgery may have a more diagnostic role, such as defining residual disease that is potentially amenable to salvage forms of therapy.

Le texte complet de cet article est disponible en PDF.

Plan


 Address reprint requests to Joseph S. Friedberg, MD, Department of Surgery, Division of Cardiothoracic Surgery, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104


© 2000  W. B. Saunders Company. Publié par Elsevier Masson SAS. Tous droits réservés.
Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 80 - N° 2

P. 633-657 - avril 2000 Retour au numéro
Article précédent Article précédent
  • HEPATIC MALIGNANCIES
  • Jane I. Tsao, Julia DeSanctis, Ricardo L. Rossi, Richard A. Oberfield
| Article suivant Article suivant
  • MULTIDISCIPLINARY APPROACH TO ESOPHAGEAL AND GASTRIC CANCER
  • Hubert J. Stein, Andreas Sendler, Ulrich Fink, J.R. Siewert

Déjà abonné à cette revue ?